



Christopher Bowen
Managing Director and Chief Regulatory Counsel
Legal Department

April 26, 2013

VIA E-MAIL

Ms. Melissa Jurgens
Office of the Secretariat
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, D.C. 20581

CONFIDENTIAL TREATMENT
REQUESTED

**Re: SUPPLEMENTAL SUBMISSION. NYMEX Submission #13-152S: Additional Supplemental Market Information Relating to the Listing of Nine Renewable Identification Number Futures Contracts.
Subject to Freedom of Information Act Protection.**

Dear Ms. Jurgens:

Previously, pursuant to Submission No. 13-152, dated April 26, 2013, the New York Mercantile Exchange, Inc. ("NYMEX" or the "Exchange") notified the Commodity Futures Trading Commission ("CFTC" or "Commission") that it was self-certifying the listing of nine (9) Renewable Identification Number (RINs) futures contracts (collectively, the "Contracts") for trading on CME Globex, the NYMEX trading floor, and for submission of clearing through CME ClearPort. The Contracts will be listed on Sunday, May, 12 2013, for trade date Monday May, 13 2013.

The Contracts will be financially-settled based on the Argus index for three (3) types of renewable fuel (D4 Biodiesel, D5 Advanced Biofuel, and D6 Ethanol), and each type will be listed for three (3) vintage years.

In this letter, the Exchange is providing the Commission with certain monthly price information applicable to the related cash market for the proposed Contracts' underlying market. The additional supplemental market information is provided in Appendix A, for which a request for confidential treatment is being simultaneously submitted to the CFTC pursuant to Rule 40.8 and Regulation 145.9(d). A copy of that request for confidential treatment is included with this supplemental filing.

NYMEX certifies that the listing of the Contracts complies with the Commodities Exchange Act and the regulations thereunder. A concise explanation and analysis of the Contracts was provided in NYMEX Submission No. 13-152. There were no substantive opposing views to the Contracts expressed to NYMEX.

The Exchange certifies that a description of the submission has been concurrently posted on the Exchange's website at <http://www.cmegroup.com/market-regulation/rule-fillings.html>.

Should you have any questions concerning the above, please contact the undersigned at (212) 299-2200. Please reference our NYMEX Submission No. 13-152S in any related correspondence.

Sincerely,

/s/ Christopher Bowen
Managing Director and Chief Regulatory Counsel

Attachments: Appendix A: Additional Supplemental Information



Christopher Bowen
Managing Director and Chief Regulatory Counsel
Legal Department

April 26, 2013

VIA E-MAIL

Stacy Easter
Paralegal Specialist
FOIA Compliance Office
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, D.C. 20581

CONFIDENTIAL TREATMENT
REQUESTED

Re: FOIA Confidential Treatment Request

Dear Ms. Easter:

By e-mail dated today, April 26, 2013, the New York Mercantile Exchange, Inc. ("NYMEX" or the "Exchange") submitted a supplemental product certification filing to the CFTC (NYMEX Submission No. 13-152S). This supplemental filing includes an appendix ("Appendix A"), which is attached.

Pursuant to Sections 8 and 8(a) of the Commodity Exchange Act ("CEA"), as amended, and Commission Regulation 145.9(d), NYMEX requests confidential treatment of Appendix A on the grounds that Appendix A contains confidential commercial information of the submitter (NYMEX). A detailed written justification for this request is attached hereto as Exhibit 1. Pursuant to Commission Regulation 145.9(d)(5), NYMEX requests that confidential treatment be maintained for Appendix A until further notice from the Exchange.

We also request that the Commission notify the undersigned immediately after receiving any FOIA request for said Appendix A or any other court order, subpoena or summons for same. Finally, we request that we be notified in the event the Commission intends to disclose such Appendix A to Congress or to any other governmental agency or unit pursuant to Section 8 of the CEA. NYMEX does not waive its notification rights under Section 8(f) of the CEA with respect to any subpoena or summons for such Appendix A.

Please contact the undersigned at (212) 299-2200 should you have any questions concerning this letter.

Sincerely,

/s/Christopher Bowen
Managing Director and Regulatory Counsel

Enclosure